IMU Imugene Ltd.

EQS-News: Imugene presents positive new data at key congress

EQS-News: Imugene Ltd
Imugene presents positive new data at key congress

06.12.2022 / 19:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Investors

Jonathan Jackson


News Source: News Direct

06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Imugene Ltd
United States
ISIN: AU000000IMU9
EQS News ID: 1506653

 
End of News EQS News Service

1506653  06.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1506653&application_name=news&site_id=research_pool
EN
06/12/2022

Underlying

IMUImugene Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Imugene Ltd.

 PRESS RELEASE
Free
IMU IMUGENE LTD.

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Tr...

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma) 10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy)1Cohort B: 4 patients were treated with azer-cel, lymphodepletion (chemotherapy)1, and interleukin 2 (IL-2) 3 complete responses - The first 2 patients treated in Cohort B achieved a complete response (CR) and 1 patient treated in Cohort A achieved a CRDurability of CRs in Cohort ...

September 3, 2024 1 EN
Free Trial
IMU IMUGENE LTD.

Imugene Limited: 1 director

A director at Imugene Limited sold 14,123,229 shares at 0.078AUD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

04/23/24 April 23, 2024 1 EN
 PRESS RELEASE
Free
IMU IMUGENE LTD.

Bile Tract Cancer expansion study opens following clearance of Imugene...

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma)Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieved a complete response and another patient achieved stable diseaseThe fifth cohort in the intratumoural (IT) arm of the VAXINIA monotherapy trial has now been cleared with no safety signals seen to date; t...

April 15, 2024 1 EN
 PRESS RELEASE
Free
IMU IMUGENE LTD.

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-V...

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXINIA efficacy, including a complete response (CR) and two partial responses (PRs), has warranted cohort expansions in biliary tract cancer and other tumour types.Compared to chemotherapy alone, vaccination with HER-Vaxx was associated with a 40% overall survival benefit.HER-Vaxx induced HER2-specific antibody levels correlate with tumo...

April 9, 2024 1 EN
 PRESS RELEASE
Free
IMU IMUGENE LTD.

Phase 1 onCARlytics solid tumour trial advances to combination arm tre...

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targeting therapeutics such as Amgen’s Blincyto®, Gilead’s Yescarta® and Imugene’s own allogeneic CAR T Azer-celOASIS potentially represents a paradigm shift in solid tumour treatmentCohort Review Committee (CRC) observed no safety issues in the onCARlytics monotherapy lead-in study and recommended opening of the combination arm of the studyOvarian, breast and melanoma patien...

March 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch